Product
LYB004
Aliases
LYB004 25µg, LYB004 50µg
1 clinical trial
1 indication
Indication
Herpes ZosterClinical trial
A Phase I, Randomized, Observer-blinded, Positive-Controlled, Dose Escalation Clinical Trial to Assess the Safety and Immunogenicity of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 YearsStatus: Not yet recruiting, Estimated PCD: 2025-02-01